Could less radiation be just as good for lymphoma?

NCT ID NCT03681535

Ongoing Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 4 times

Summary

This study is testing whether a lower dose of radiation (20 Gy instead of 30 Gy) can still control diffuse large B-cell lymphoma in patients who had a good response to chemotherapy. About 241 participants will receive the reduced radiation to see if it keeps the cancer from coming back while causing fewer side effects. The goal is to maintain high local control rates with less toxicity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy
What this could lead to: If successful, this could mean that many lymphoma patients can receive a lower, safer dose of radiation without compromising cancer control.
What could go wrong: This is a mid-stage study with 241 participants, so results are not yet confirmed. Lower radiation might not control the cancer as well as the standard dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital

Weymouth, Massachusetts, 02190, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Juntendo University

Tokyo, Japan
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
National Cancer Center of Singapore

Singapore, Singapore
University Hospital Motol

Prague, Czechia
University of Rochester James P. Wilmot Cancer Institute

Rochester, New York, 14642, United States
University of Torino

Torino, Italy
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Yonsei University Health System

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.